Theranexus (EPA:ALTHX) | Finanzwire

Basculer en Français

10109	Companies
207175	Keywords
137297	Articles
109801	Press releases

Home
Companies
Theranexus

BRIEF

published on 12/17/2024 at 18:20, 1 year 3 months ago

Theranexus optimizes its cash flow and extends its financial horizon

Treasury Funding License Agreement Theranexus Batten Disease
PRESS RELEASE

published on 12/17/2024 at 18:15, 1 year 3 months ago

THERANEXUS PRESENTS AN UPDATE OF ITS CASH POSITION AND FINANCING HORIZON
Theranexus presents an update of its cash position and cash flow horizon, expecting improvement through upcoming payments and restructuring agreement with banking partners

Cash Position Cash Flow Financial Debt Theranexus Banking Partners
BRIEF

published on 12/17/2024 at 18:05, 1 year 3 months ago

License agreement between Theranexus and Exeltis for TX01

Rare Diseases License Agreement Theranexus Exeltis TX01
PRESS RELEASE

published on 12/17/2024 at 18:00, 1 year 3 months ago

THERANEXUS AND EXELTIS (INSUD PHARMA) ANNOUNCE LICENSING AGREEMENT TO COMMERCIALIZE THERANEXUS TX01 FOR TWO RARE NEUROLOGICAL DISORDERS
Theranexus and Exeltis sign license agreement for TX01, expanding treatment for rare neurological diseases. Exeltis to market TX01 across Europe and other regions

License Agreement Theranexus Neurological Diseases Exeltis TX01
BRIEF

published on 11/19/2024 at 18:05, 1 year 4 months ago

Theranexus presents positive results for the treatment of Batten disease CLN3

Clinical Trial Theranexus Batten-1 Batten Disease Visual Acuity
PRESS RELEASE

published on 11/19/2024 at 18:00, 1 year 4 months ago

Update on the Theranexus' Batten-1 project in CLN3 Batten's disease
Theranexus and BBDF present positive results of Batten-1 trial in CLN3 Batten disease patients, showing safety and efficacy of miglustat. Expanded use indicates potential in visual acuity stabilization

Theranexus BBDF Batten-1 Trial CLN3 Batten Disease Miglustat
BRIEF

published on 10/23/2024 at 18:05, 1 year 5 months ago

Theranexus Announces Its Cash Position as of September 30, 2024

Treasury Batten Disease Miglustat Research Tax Credit Industrial Partnerships
PRESS RELEASE

published on 10/23/2024 at 18:00, 1 year 5 months ago

THERANEXUS ANNOUNCES ITS CASH POSITION AS OF SEPTEMBER 30, 2024
Theranexus reports €1.9 million cash position as of September 30, 2024, with plans for product registrations and phase 3 trials in rare neurological diseases

Cash Position Biopharmaceutical Theranexus Rare Neurological Diseases Product Registrations
BRIEF

published on 10/17/2024 at 18:05, 1 year 5 months ago

Theranexus partners with Synerlab for a breakthrough in the treatment of Niemann-Pick C

Theranexus EMA Synerlab Miglustat Niemann-Pick C
PRESS RELEASE

published on 10/17/2024 at 18:00, 1 year 5 months ago

THERANEXUS JOINS UP WITH SYNERLAB TO PREPARE THE COMMERCIALIZATION OF ITS PEDIATRIC FORMULATION IN NIEMANN-PICK TYPE C DISEASE
Theranexus partners with Synerlab to produce oral solution of miglustat for Niemann-Pick type C disease, aiming for EMA approval and commercialization by 2026. Novel pediatric formulation Mig-OS provides new therapeutic option for NPC patients

Theranexus Synerlab Miglustat Niemann-Pick Type C Disease EMA Approval

Accesswire

Published on 03/30/2026 at 00:15, 25 minutes ago

$520,000 Cash R&D Tax Refund Received
Published on 03/29/2026 at 12:15, 12 hours 25 minutes ago

China Xlx Announces 2025 Annual Results Deepening Efforts in Reducing Costs, Enhancing Efficiency, Strengthening Competitiveness Through Differentiation and Driving Marketing Transformation
Published on 03/28/2026 at 01:00, 1 day 22 hours ago

Battery X Metals Announces Confidential Submission of Amended Draft Registration Statement with the U.S. Securities and Exchange Commission in Connection with Proposed U.S. National Securities Exchange Initial Public Offering
Published on 03/28/2026 at 00:55, 1 day 22 hours ago

Notification of Relevant Change to Significant Shareholder
Published on 03/28/2026 at 00:50, 1 day 22 hours ago

"Rise" Selected as NASA Artemis II Moon Mascot

View all ACCESSWIRE

EQS Group

Published on 03/29/2026 at 17:05, 7 hours 35 minutes ago

FAST III trial demonstrates non-inferiority of CAAS vFFR to invasive wire-based FFR
Published on 03/28/2026 at 10:05, 1 day 14 hours ago

Hisense Advances a Quiet Green Revolution in Home Entertainment
Published on 03/28/2026 at 08:56, 1 day 15 hours ago

Turkiye Garanti Bankasi A.S.: Sale of Garanti Bank S.A. and our public disclosure dated 10.03.2026
Published on 03/28/2026 at 01:42, 1 day 21 hours ago

EQS-Adhoc: Raiffeisen Bank International AG: Agreement on the acquisition of Garanti BBVA Group Romania
Published on 03/27/2026 at 21:58, 2 days 2 hours ago

Kaufman & Broad SA: Availability of the Universal Registration Document 2025

Les Echos

Published on 03/27/2026 at 19:06, 2 days 5 hours ago

Mersen: Disclosure of trading own shares
Published on 03/27/2026 at 18:52, 2 days 5 hours ago

Crédit Agricole CIB announces the publication of its 2025 Universal Registration Document
Published on 03/27/2026 at 18:40, 2 days 6 hours ago

2026 share capital increase reserved for members of the Saint-Gobain Group employee savings plan
Published on 03/27/2026 at 17:53, 2 days 6 hours ago

Publication of Carrefour's 2025 Universal Registration Document
Published on 03/27/2026 at 17:45, 2 days 6 hours ago

PUBLICATION OF THE UNIVERSAL REGISTRATION DOCUMENT FISCAL YEAR 2025

View all LES ECHOS COMFI WIRE